Trying for another deal

Valeant, the acquisitive speciality pharma company, recently turned its sights on US drugmaker Cephalon, with a $5.7bn hostile offer to acquire the biotech company. Unsatisfied with the speed at which the Cephalon board was responding, Valeant Chief Executive Mike Pearson has taken the offer directly to the shareholders with an all-cash deal